TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04017390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theraworx Foam
Description: Apply Theraworx Foam alone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Foam
Description: Apply placebo foam alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theraworx Foam and night splint
Description: Apply Theraworx Foam and night time splint

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Foam and night time splint
Description: Apply placebo foam and night time splint
Study: NCT06207643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: removing carotid artery atheromatous plaque surgically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: removing carotid artery atheromatous plaque surgically
Study: NCT05434299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFX05-01
Description: TFX05-01 for intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFX05-01
Description: TFX05-01 for intravenous
Study: NCT05157516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinea block
Description: the patients will receive a single injection erector spinea block after induction of general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural block
Description: the patients will receive caudal epidural block after induction of general anesthesia
Study: NCT05015764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Management
Description: Removal of excess extracellular fluid using diuretics

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Cardiovascular System
Description: System with Fluid Management Module
Study: NCT04844918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06243783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Imaging Stress Test
Description: In the Montreal Imaging Stress Test, participants are required to solve basic mathematical tasks, but the allowed reaction time is set lower than their average.
Study: NCT05185518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of novel insulin injection port
Description: use subcutaneous port into which glucose monitor is embedded
Study: NCT06031597

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
Study: NCT06522945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQD3524
Description: Polymyxin antibiotics
Study: NCT05761210

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection
Study: NCT05120466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AD IT UP media literacy intervention
Description: AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual health education curriculum
Description: The school's regular health education curriculum includes classroom lectures, hands on activities and group work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual health education curriculum
Description: The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
Study: NCT05479604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic
Description: Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
Study: NCT06178653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Control Training
Description: Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
Study: NCT05436964

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
Study: NCT05477706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Support for Progress (PSP)
Description: Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Referral (TR)
Description: TR consists of detailed resource information and referral, consistent with standard practice.
Study: NCT06489691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Description: 6-minute walk test (6MWT) will be performed according to clinical standards
Study: NCT06128174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Farawave PFA catheter
Description: The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.
Study: NCT05514574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: hussoni duseni  music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: Stress ball squeeze
Study: NCT05033080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-121/TEZ/D-IVA)
Description: Placebo matched to VX-121/TEZ/D-IVA for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.
Study: NCT05424224

Intervention type: DEVICE
Intervention: MagVita
Description: rTMS system
Study: NCT04801745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy vegan diet
Description: Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy vegan diet
Description: Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Plate - Low Purine
Description: Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Plate - Low Purine
Description: Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amla fruits
Description: Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amla fruits
Description: Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
Study: NCT05408143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced telemedicine (ETM)
Description: An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, \& ears, auscultate the heart \& lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations.
Study: NCT06448455

Intervention type: OTHER
Intervention: Observation
Description: Collect relevant data of patients
Study: NCT05236621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg dexamethasone tablets administered orally
Study: NCT06473454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and basic body awareness therapy ( exercise)
Description: exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and basic body awareness therapy ( exercise)
Description: exercise
Study: NCT04522973

Intervention type: OTHER
Group type: OTHER
Intervention: Beverage with ethanol and E-cigarette liquid with ethanol
Description: Beverage with ethanol and E-cigarette liquid with ethanol

Intervention type: OTHER
Group type: OTHER
Intervention: Beverage with ethanol and E-cigarette liquid without ethanol
Description: Beverage with ethanol and E-cigarette liquid without ethanol

Intervention type: OTHER
Group type: OTHER
Intervention: Beverage without ethanol and E-cigarette liquid with ethanol
Description: Beverage without ethanol and E-cigarette liquid with ethanol

Intervention type: OTHER
Group type: OTHER
Intervention: Beverage without ethanol and E-cigarette liquid without ethanol
Description: Beverage without ethanol and E-cigarette liquid without ethanol
Study: NCT04926103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota transplant (FMT)
Description: Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
Study: NCT06090903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review Medical Chart
Study: NCT05969392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradiscal Gelified Ethanol
Description: Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
Study: NCT04550676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT (intervention)
Description: Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CME (active control)
Description: Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
Study: NCT05272735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine (Recombinant)
Description: Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
Study: NCT03417921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812 in combination with gemcitabine and nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and nab-paclitaxel
Description: Gemcitabine and nab-paclitaxel as standard pattern

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and nab-paclitaxel
Description: Gemcitabine and nab-paclitaxel as standard pattern
Study: NCT04992936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extract from the wine industry
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study: NCT05970549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRAflow® Active Fluid Exchange System
Description: All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.~Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional extraventricular drain
Description: The retrospective analysis will be performed on the last 60 traditional external ventricular drains.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-contrast head CTs
Description: Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.